Skip to content

Topical application of tranexamic acid for postoperative blood loss, inflammation, coagulation, fibrinolysis, and knee function in patients with gouty knee arthritis undergoing arthroscopic debridement

Topical application of tranexamic acid for postoperative blood loss, inflammation, coagulation, fibrinolysis, and knee function in patients with gouty knee arthritis undergoing arthroscopic debridement

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000032050
Enrollment
Unknown
Registered
2020-04-18
Start date
2020-07-17
Completion date
Unknown
Last updated
2020-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gouty knee arthritis

Interventions

B:Topical application of 1.5g/50mL TXA through drainage, and drain clamping for 3 h
C:Topical application of 3.0 g/50mL TXA through drainage, and drain clamping for 3 h

Sponsors

Department of Orthopaedic Surgery, West China Hospital, West China Medical School, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) The patients with knee gouty arthritis undergoing arthroscopic arthrolysis; (2) Normal platelet and coagulation function preoperatively; (3) Normal intravenous ultrasound in the lower extremities preoperatively; (4) To be able to and willing to provide signed informed consent.

Exclusion criteria

Exclusion criteria: (1) Systemic infections such as pulmonary infection or urinary tract infection are not controlled preoperatively; (2) Abnormal immune function or combined immune-related disease preoperatively; (3) Abnormal inflammatory index preoperatively (C-reactive protein >20 mg/L); (4) Abnormal fibrinolysis index preoperatively (FDP > 5mg/L); (5) Discontinuation of oral anticoagulants or aspirin less than 1 week; (6) Allergy to tranexamic acid; (7) High-risk patients with thrombosis, including atrial fibrillation, pacemaker and stent implantation; (8) History of venous thromboembolism, pulmonary embolism, cerebral infarction, coronary heart disease; (9) Patients with severe liver and kidney dysfunction.

Design outcomes

Primary

MeasureTime frame
Blood loss;Drainage;ESR, CRP, IL-6, IL-10;

Secondary

MeasureTime frame
Hb;Hct;DVT, PE;Transfusion;Swelling;VAS pain score;color Doppler Ultrasonic (CDU) examination in lower extremity;ROM;Muscle strength;Coagulation index;Satisfaction scores;Sleep quality;

Countries

China

Contacts

Public ContactJian Li

West China Hospital, Sichuan University

18980601388@163.com+86 18980601388

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026